Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.
Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.
复制标题
乳腺癌中 PTEN 表达缺失：与临床病理特征和预后的相关性
DOI：
10.18632/oncotarget.16761
复制
发表时间：
2017-05-09
期刊：
影响因子：
--
通讯作者：
Yang J
中科院分区：
文献类型：
--
作者：
Li S;Shen Y;Wang M;Yang J;Lv M;Li P;Chen Z;Yang J
许多研究已经评估了PTEN（10号染色体缺失的磷酸酶和张力蛋白同源物）表达在乳腺癌中的意义，但他们的结果仍然存在争议。我们进行了一项荟萃分析，以评估乳腺癌中PTEN表达与临床病理特征和预后的关系。检索PubMed、Embase、Web of Science和中国国家知识基础设施，以识别相关出版物。然后通过荟萃分析的比值比（OR）和风险比（HR）及95%置信区间（CI）评估PTEN表达与临床病理参数、无病生存期（DFS）和总生存期（OS）之间的相关性。基于涉及10，231名患者的27项研究，汇总结果显示，与正常组织相比，乳腺癌中的PTEN缺失明显更常见（OR = 12.15，95%CI = 6.48-22.79，P < 0.00001），PTEN缺失与肿瘤体积增大明显相关（> 2 cm，OR = 0.62，95%CI = 0.48-0.82，P = 0.0006），淋巴结转移（OR = 0.61，95%CI = 0.45-0.82，P = 0.0001），TNM分期较晚（III-IV期，OR = 0.55，95%CI = 0.35-0.86，P = 0.009），分化差（OR = 0.37，95% CI = 0.24-0.59，P < 0.0001），高侵袭性三阴性表型（OR = 1.62，95% CI = 1.23-2.12，P = 0.0005）。此外，PTEN缺失的患者表现出显著更差的DFS和OS（分别为HR = 1.63，95% CI = 1.04-2.22，P < 0.00001; HR = 1.41，95% CI = 1.08-1.73，P < 0.0001）。总之，在乳腺癌患者中，PTEN缺失可能预示着更积极的行为和更糟糕的结果。
Various studies have evaluated the significance of PTEN (phosphatase and tensin homolog deleted from chromosome 10) expression in breast cancer, but their results remain controversial. We conducted a meta-analysis to evaluate the associations of PTEN expression with clinicopathological characteristics and prognosis in breast cancer. PubMed, Embase, Web of Science, and China National Knowledge Infrastructure were searched to identify relevant publications. The associations between PTEN expression and clinicopathological parameters, disease-free survival (DFS), and overall survival (OS) were then assessed via meta-analyses of odds ratio (ORs) and hazard ratio (HRs) with 95% confidence intervals (CIs). Based on 27 studies involving 10,231 patients, the pooled results revealed that PTEN loss was significantly more common in breast cancer than in normal tissues (OR = 12.15, 95% CI = 6.48–22.79, P < 0.00001) and that PTEN loss had clear associations with larger tumor size (> 2 cm, OR = 0.62, 95% CI = 0.48–0.82, P = 0.0006), lymph node metastasis(OR = 0.61, 95% CI = 0.45–0.82, P = 0.0001), later TNM stage(stage III–IV, OR = 0.55, 95% CI = 0.35–0.86, P = 0.009), poor differentiation(OR = 0.37, 95% CI = 0.24–0.59, P < 0.0001), and the highly aggressive triple-negative phenotype (OR = 1.62, 95% CI = 1.23–2.12, P = 0.0005). Moreover, patients with PTEN loss exhibited significantly worse DFS and OS(HR = 1.63, 95% CI = 1.04–2.22, P < 0.00001; HR = 1.41, 95% CI = 1.08–1.73, P < 0.0001; respectively). In conclusion, PTEN loss might predict more aggressive behavior and worse outcomes in patients with breast cancer.